Tag Archives: (LLY)

The 3% Difference That Doesn’t Matter

My dentist called last week to reschedule my cleaning. “Supply chain issues with the numbing gel,” he said apologetically. Funny how even the medical profession struggles with simple logistics these days. This got me thinking about how the simplest innovations often create the biggest disruptions, and how I’ve been around long enough to recognize them […]

The Grumpy Husband’s Guide To Getting Rich

I was having lunch with a buddy in Palo Alto last week when he mentioned that his wife’s doctor just prescribed her Ozempic. “Cost me eight hundred bucks for a month’s supply,” he grumbled, stabbing his salad. That’s when it hit me. We’re living through one of those rare moments when an entire industry gets […]

Blink And You Miss It

Did you know that the average person blinks about 17,000 times a day? Well, if you blinked during the American Diabetes Association conference, you might have missed Eli Lilly (LLY) delivering some of the most impressive clinical data I’ve seen in years. While their competitors stumbled through disappointing presentations, Lilly quietly demonstrated why they’re positioning […]

The Art Of War, Immunology Edition

Last month, as I pored over pharma earnings with a strong espresso and a stronger sense of deja vu, I was reminded why I swapped the lab coat for a Bloomberg terminal four decades ago. Markets may not speak Latin, but they sure know how to butcher nuance. And AbbVie (ABBV), dear readers, is a […]